These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36214062)

  • 1. Assessment of the Systemic Sclerosis-Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short-Form Development.
    Yu L; Domsic RT; Saketkoo LA; Withey J; Frech TM; Herrick AL; Hummers LK; Shah AA; Denton CP; Khanna D; Pauling JD
    Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1725-1734. PubMed ID: 36214062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.
    Pauling JD; Domsic RT; Saketkoo LA; Almeida C; Withey J; Jay H; Frech TM; Ingegnoli F; Dures E; Robson J; McHugh NJ; Herrick AL; Matucci-Cerinic M; Khanna D; Hewlett S
    Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1373-1384. PubMed ID: 29473715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of internet-based information for individuals with Raynaud's phenomenon and patients with systemic sclerosis.
    Devgire V; Martin AF; McKenzie L; Sandler RD; Hughes M
    Clin Rheumatol; 2020 Aug; 39(8):2363-2367. PubMed ID: 32152916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity.
    Pauling JD; Reilly E; Smith T; Frech TM
    Arthritis Care Res (Hoboken); 2019 Aug; 71(8):1119-1126. PubMed ID: 30133174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.
    Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
    Clin Rheumatol; 2022 Oct; 41(10):3049-3054. PubMed ID: 35583625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.
    Pauling JD; Frech TM; Hughes M; Gordon JK; Domsic RT; Anderson ME; Ingegnoli F; McHugh NJ; Johnson SR; Hudson M; Boin F; Ong VH; Matucci-Cerinic M; Altorok N; Scolnik M; Nikpour M; Shah A; Pope JE; Khanna D; Herrick AL
    J Scleroderma Relat Disord; 2018 Oct; 3(3):249-252. PubMed ID: 30705970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a patient-reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HAnDE) scale.
    Sibeoni J; Dunogué B; Dupont A; Haiddar D; Benmostefa N; Falissard B; Mouthon L; Révah-Levy A; Verneuil L
    Br J Dermatol; 2022 Jan; 186(1):96-105. PubMed ID: 34355380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud's phenomenon-an update on diagnosis, classification and management.
    Pauling JD; Hughes M; Pope JE
    Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
    Ingegnoli F; Carmona L; Castrejon I
    Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a new patient-reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17-item Scleroderma Functional scale.
    Daste C; Abdoul H; Foissac F; Papelard A; Alami S; Kwakkenbos L; Carrier ME; Lefèvre-Colau MM; Thombs BD; Poiraudeau S; Rannou F; Mouthon L; Nguyen C
    Br J Dermatol; 2020 Oct; 183(4):710-718. PubMed ID: 32017013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The patient experience of Raynaud's phenomenon in systemic sclerosis.
    Pauling JD; Saketkoo LA; Matucci-Cerinic M; Ingegnoli F; Khanna D
    Rheumatology (Oxford); 2019 Jan; 58(1):18-26. PubMed ID: 29538754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.
    Becker MO; Dobrota R; Garaiman A; Debelak R; Fligelstone K; Tyrrell Kennedy A; Roennow A; Allanore Y; Carreira PE; Czirják L; Denton CP; Hesselstrand R; Sandqvist G; Kowal-Bielecka O; Bruni C; Matucci-Cerinic M; Mihai C; Gheorghiu AM; Mueller-Ladner U; Sexton J; Kvien TK; Heiberg T; Distler O
    Ann Rheum Dis; 2022 Apr; 81(4):507-515. PubMed ID: 34824049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International consensus criteria for the diagnosis of Raynaud's phenomenon.
    Maverakis E; Patel F; Kronenberg DG; Chung L; Fiorentino D; Allanore Y; Guiducci S; Hesselstrand R; Hummers LK; Duong C; Kahaleh B; Macgregor A; Matucci-Cerinic M; Wollheim FA; Mayes MD; Gershwin ME
    J Autoimmun; 2014; 48-49():60-5. PubMed ID: 24491823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
    Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.
    Wilkinson JD; Leggett SA; Marjanovic EJ; Moore TL; Allen J; Anderson ME; Britton J; Buch MH; Del Galdo F; Denton CP; Dinsdale G; Griffiths B; Hall F; Howell K; MacDonald A; McHugh NJ; Manning JB; Pauling JD; Roberts C; Shipley JA; Herrick AL; Murray AK
    Arthritis Rheumatol; 2018 Jun; 70(6):903-911. PubMed ID: 29457381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Turkish version of the Scleroderma Health Assessment Questionnaire.
    Temiz Karadag D; Karakas F; Tekeoglu S; Yazici A; Isik OO; Cefle A
    Clin Rheumatol; 2019 Jul; 38(7):1917-1923. PubMed ID: 30840212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.